An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

Familial HLH is a success story in modern medicine. Initially a disease that ... to be 4.2 cases per 1 million population in 2018 in England. 15 The annual incidence of HLH associated with cancer ...

The development of simple, reliable ultraviolet and visible spectrophotometers within the last ten years has made available an analytical tool of great versatility and power. The role played by ...

The advent of new drugs to treat tuberculosis and enhanced ... the Institute of Tropical Medicine supported site laboratories and performed additional testing. Procedures included smear microscopy ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin-resistant tuberculosis, according to a study published in the Jan.